Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Capital Expenditures (2017 - 2021)

Cogent Biosciences (COGT) has 3 years of Capital Expenditures data on record, last reported at $433000.0 in Q4 2021.

  • For Q4 2021, Capital Expenditures changed N/A year-over-year to $433000.0; the TTM value through Dec 2021 reached $1.6 million, changed N/A, while the annual FY2025 figure was $1.6 million, 171.2% up from the prior year.
  • Capital Expenditures reached $433000.0 in Q4 2021 per COGT's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.2 million in Q3 2021 and bottomed at -$27000.0 in Q2 2018.
  • Average Capital Expenditures over 3 years is $272250.0, with a median of $75000.0 recorded in 2018.
  • The widest YoY moves for Capital Expenditures: up 61.11% in 2019, down 104.7% in 2019.
  • A 3-year view of Capital Expenditures shows it stood at $468000.0 in 2018, then plummeted by 97.22% to $13000.0 in 2019, then skyrocketed by 3230.77% to $433000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $433000.0 in Q4 2021, $1.2 million in Q3 2021, and $13000.0 in Q4 2019.